Abstract:The management of neuroendocrine neoplasia remains a perplexing problem because of the lack of knowledge of the biology of the disease, its late presentation, the relative insensitivity of imaging modalities and a paucity of predictably effective treatment options. A critical limitation is posed by the lack of accurate biomarkers to guide management, monitor the efficacy of therapy and provide a prognostic assessment of disease progress. Currently utilized monoanalyte biomarkers (e.g. chromogranin, serotonin, pancreastatin etc.) exhibit variable metrics, poor sensitivity, specificity, and predictive ability and are rarely used to guide clinical decision making. A National Cancer Institute Neuroendocrine Tumor summit conference held in 2007 noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumors. Nevertheless little progress has been made in this field until recently with the consideration of blood transcript analysis, circulating tumor cells and miRNA measurement. Given the complexity and multidimensionality of the neoplastic process itself, the heterogeneity of neuroendocrine tumors (NET) as well as the interaction of the tumor microenvironment, it is not unexpected that no single (monoanalyte) biomarker has proven to be effective. This deduction reflects the growing recognition that use of a monoanalyte to define a multidimensional disease process has inherent flaws. Logic dictates that no single measured parameter can capture the pathobiological diversity of neoplasia and monoanalytes cannot define the multiple variables (proliferation, metabolic activity, invasive potential and metastatic propensity) that constitute tumor growth. Thus far, most biomarkers whether in tissue or blood/urine have been single analytes with varying degrees of sensitivity and specificity and in general have failed to exhibit robust metrics or lacked methodological rigor. Neuroendocrine (NE) disease represents an area of biomarker paucity since the individual biomarkers (gastrin, insulin etc) are not widely applicable to the diverse types of NE neoplasia (NEN). Broad spectrum markers such as CgA have limitations in sensitivity, specificity and reproducibility. This review serves to provide a general background of the evolution of NET biomarkers. It provides an assessment of their current and past usage and limitations in assessing their diagnostic, pathologic and prognostic aspects in respect of NET. It provides a view of the changing methodology of biomarker development and the application of biomathematical analyses to redefining detection and treatment. Finally, it presents a description and consensus on current advances in transcript analysis, miRNA measurement and circulating tumor cell identification.

Current Perspective On The Pathogenesis Of Small Intestinal Neuroendocrine Tumors: Progress In Biomarkers And Molecular Events

Survival Outcomes and Surgical Intervention of Small Intestinal Neuroendocrine Tumors: a Population Based Retrospective Study

Advances in small intestinal neuroendocrine tumor treatment

Research advances in nicotinamide N-methyltransferase as a potential tumor biomarker

Potential Effective Diagnostic Biomarker in Patients with Primary and Metastatic Small Intestinal Neuroendocrine Tumors

Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Pathologic research update of colorectal neuroendocrine tumors.

Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

Clinicopathological Features And Prognostic Factors Of Colorectal Neuroendocrine Neoplasms

Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review

[Advances in Basic and Translational Research in Neuroendocrine Neoplasms].

Various Markers of Neuroendocrine Tumor: A Narrative Review

Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study

Incidence, survival, and prognostic nomogram of patients with small intestinal neuroendocrine tumors: A SEER population-based study

The Role of Small-Bowel Endoscopy in the Diagnosis and Management of Small-Bowel Neuroendocrine Tumours

Updates on precision medicine of pancreatic neuroendocrine tumor

Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications

Diagnostics of neuroendocrine tumours

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives